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Abstract
Background: Disseminated intravascular coagulation (DIC) is a pathological disturbance of the complex balance
between coagulation and anticoagulation that is precipitated by vascular injury, acidosis, endotoxin release and/
or sepsis and characterized by severe bleeding and excessive clotting. The innately low levels of coagulation
factors found in newborn infants place them at extremely high risk for DIC. Anecdotal reports suggest that either
anticoagulant or fibrinolytic therapy may alleviate some of the manifestations of DIC. To test the hypothesis that
replacement of both anticoagulants and fibrinolytics may improve survival and outcome better than either single
agent or supportive care alone, we utilized a neonatal piglet model of endotoxin-induced DIC.
Methods: DIC was induced in twenty-seven neonatal pigs (7 to 14 days of age) by intravenous administration of
E. coli endotoxin (800 μg/kg over 30 min). The piglets were divided into 4 groups on the basis of treatment
protocol [A: supportive care alone; B: Antithrombin III (AT, 50 μg/kg bolus, 25 μg/kg per hr continuous infusion)
and supportive care; C: Recombinant Tissue Plasminogen Activator (R-TPA, 25 μg/kg per hr continuous infusion)
and supportive care; D: AT, R-TPA and supportive care] and monitored for 3 primary outcome parameters
(survival time, macroscopic and microscopic organ involvement) and 4 secondary outcome parameters
(hematocrit; platelet count; fibrinogen level; and antithrombin III level).
Results: Compared with supportive care alone, combination therapy with AT and R-TPA resulted in a significant
improvement of survival time, hematocrit, AT level, macroscopic and microscopic organ involvement, p < 0.05.
Compared with supportive care alone, R-TPA alone significantly reduced macroscopic organ involvement and AT
alone increased AT levels.
Conclusion: The findings suggest that combining AT, R-TPA and supportive care may prove more advantageous
in treating the clinical manifestations of DIC in this neonatal pig model than either single modality or supportive
care alone.
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Background
DIC is a combination of enhanced thrombosis and
decreased fibrinolysis. It is precipitated by some underly-
ing disorder, e.g. sepsis, that results in production and
release of proinflammatory cytokines. These activate the
coagulation cascade, inhibit physiologic anticoagulant
pathways, and depress fibrinolysis, resulting in enhanced
fibrin formation and impaired fibrin removal [1].
Initiated by either contact phase or tissue factor activation,
the coagulation cascade is a set of reactions involving mul-
tiple coagulation factors and cofactors [2] that result in the
generation of thrombin which acts on the fibrin polymer
to produce a fibrin clot [3]. This process is subject to reg-
ulation by intrinsic inhibitors, e.g. AT and protein C. One
of the major inhibitors of coagulation is AT. It rapidly
binds and inactivates thrombin and factor Xa by forming
thrombin-antithrombin and factor Xa-antithrombin com-
plexes [4]. Protein C is a vitamin K-dependent inactive
enzyme precursor that when activated, proteolytically
inactivates the activated factors VIII and V by way of cleav-
age reactions.[5]
The fibrinolytic pathway is a set of reactions involving
fibrinolytic factors and cofactors [2] that clear unneeded
fibrin from intravascular and extravascular sites [4]. Dur-
ing fibrinolysis, plasminogen is cleaved by tissue plas-
minogen activator (TPA) or urokinase-type plasminogen
activator to form plasmin that lyses the fibrin clot, releas-
ing fibrin degradation products. During DIC, thrombin
generation proceeds via the extrinsic tissue factor/factor
VIIa route with simultaneous depression of inhibitory
mechanisms, such as AT and Protein C [1] and enhanced
inhibition of fibrinolysis by plasminogen activator inhib-
itor (PAI-1) [6].
Neonates are innately predisposed to acquire DIC due to
altered levels of coagulation and fibrinolytic proteins that
differ markedly from those in adults [5,7]. In neonates, AT
levels are within the concentration range at which sponta-
neous thromboses could occur in adults. Protein C and
Protein S are reduced at birth to 30% of adult plasma con-
centrations and remain decreased during the first weeks of
life [5]. In addition, differences in plasma concentrations
of fibrinolytic proteins may also contribute to predisposi-
tion for DIC [7]. At birth, newborn plasminogen levels are
58% of adult concentrations while plasma concentrations
of PAI-1 and TPA are approximately twice adult concen-
trations and decrease to adult plasma concentration val-
ues by day 5 of life [5]. Impaired fibrin degradation, due
to high circulating levels of PAI-1, contributes to
enhanced intravascular fibrin deposition [1].
Furthermore, sepsis, a major risk factor for DIC, occurs in
infants with an incidence of 1 to 5 per 1,000 live births.
Mortality is high in the septic neonate, up to 50% for early
onset-sepsis [8]., and survivors often exhibit increased
morbidity. Hypercoagulability is often seen during sepsis.
Fibrin deposition leads to microvascular and less fre-
quently, large vessel thrombosis with impaired perfusion
and subsequent organ damage [9]. These microvascular
thrombi in various organs contribute to the development
of multiorgan failure [4]. Neonates surviving an episode
of DIC may be left with the burden of such sequelae and
diminished quality of life. For these reason, effective ther-
apy for DIC would have tremendous impact.
Unfortunately, the therapy for DIC in the neonate is by no
means optimal. The current mainstay of therapy is "treat-
ment of the underlying illness" and supportive care. The
efficacy of coagulant replacement therapy in the overall
treatment of DIC in the septic infant is controversial.
Gross, et al. reviewed a group of infants with sepsis and
DIC and concluded that successful outcome depended on
treatment of the underlying illness and that therapy
directed toward the coagulopathy did not result in
improved outcomes [10]. However, Gross used a nonspe-
cific global approach by administering fresh frozen
plasma to replace diminished coagulation factors.
Specific treatment directed toward either the coagulation
or fibrinolytic derangement has occasionally been
attempted. Previous studies suggest that a unilateral
approach to the coagulation or fibrinolytic deficiencies
may be of some benefit (Table 1). Most of the human
studies were performed in children or adolescents.
Because of ethical concerns, controlled studies with
neonates are difficult and limited data are available. The
animal studies performed so far have focused mainly on
correction of anticoagulation defects, although Munoz, et
al. addressed both the anticoagulation and fibrinolytic
abnormality using a rabbit model [11]. The current study
utilizes a newborn piglet model of endotoxin-induced
DIC to mimic sepsis and examines the effect of replacing
AT and R-TPA singly and in combination. Both are cur-
rently available for human use. The newborn piglet was
chosen as it is the closest non-primate animal model of
the human neonate with respect to anatomy, physiology,
biochemistry and metabolism [12]. The hemostatic sys-
tem in the pig is very similar to that of the human
adult[13,14]. Table 2 compares normal coagulation val-
ues with reference intervals for the pig and human [15].
Massicotte, et al. considered the newborn piglet to be a
suitable model for investigation of specific hemorrhagic
and thrombotic problems in the newborn [13].
The major goal of this experiment was to test the hypo-
thesis that replacement of both AT and R-TPA would
improve survival and decrease the severity of the diseaseThrombosis Journal 2006, 4:7 http://www.thrombosisjournal.com/content/4/1/7
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in the neonate better than either single agent or support-
ive care alone.
Methods
Twenty-seven newborn piglets, 7–14 days old, were ran-
domly divided into four groups on the day of experiment
(Table 3). Each group received supportive care with or
without some other form of therapy. Supportive care
included maintenance intravenous fluids (5% dextrose
and 1/2 normal saline, 150 ml/kg/day); respiratory sup-
port (tidal volume 15 ml/kg, ventilator rate 20/min, FiO2
1.0); volume expansion for decreased mean blood pres-
sure (BP < 30 mm Hg), or central venous pressure (CVP <
5 cm H2O) and/or urine output (< 1 ml/kg/hr for more
than 2 hours); and dopamine/dobutamine administra-
tion (5–15 μg/kg per min) for hypotension unresponsive
to a cumulative volume expansion of 60 ml/kg. Group A
received supportive care only. Group B received AT (50
μg/kg bolus, and 25 μg/kg continuous intravenous infu-
sion) and supportive care. Group C received R-TPA (0.025
Table 1: Summary of selected therapeutic approaches using replacement of specific anticoagulation and fibrinolytic proteins to treat 
DIC. This table is based on a PubMed search using the key words: "Disseminated Intravascular Coagulation", "Therapy for DIC", 
"Animal experimentation on DIC" and "Neonate or Newborn." A representative selection was chosen from a total of 98 papers in the 
period 1970 to 2005 to give an overview of the literature on this subject.
Subject Mortality Rate N Therapeutic 
Factor
Provoking Factor Outcome Reference
Coagulation Pathway
Children not addressed 4 Protein C meningococcemia reversed organ 
dysfunction
[16]
Infants, adolescents 25% 8 Protein C meningococcemia restored micro-
circulation
[17]
Children 1 mo-5 yr 17% 6 AT sepsis, carcinoma, 
Reye's
normalized coagulation 
studies
[18]
Newborns 40% 10 AT, heparin sepsis improved coagulation [22]
Child 100% 1 AT, Protein C Unknown, ARDS stopped bleeding [19]
Baboons 67–100% 3 Protein C E. coli organisms prevented 
coagulopathy, lethal 
effects
[25]
Adult pigs not addressed 16 AT E. coli endotoxin Improved MAP, SVR [23]
Guinea pigs 0% with Tx 58 Antithrombin 
Concentrate & 
LMWH
S. aureus isolates Decreased fibrin 
deposits, improved 
survival
[26]
Adult pigs Not addressed AT LPS decreased DIC, 
improved survival
[21]
Adult pigs Not addressed 21 AT LPS reduced effusion, 
edema
[27]
Newborn and 3 wk 
old piglets
Not Addressed >>16/age group
& dose
Heparin 125I-Fibrinogen ↑ AT conc. Improved 
the antithrombotic 
effects of heparin
[28]
Fibrinolytic Pathway
Infant, 4 mo 0% N 1 R-TPA meningococcemia improved organ 
perfusion, cardiac 
performance
[24]
Infants 0% 2 R-TPA Meningococcemia Improved micro-
circulation
[20]
Combined Coagulation and Fibrinolytic Pathways
Adult rabbits 70 → 40% R-TPA 
alone, 70 → 0% 
both factors
N R-TPA, R-hirudin endotoxin Improved hemostatic 
markers, decreased 
fibrin deposits
[11]
Legend: ARDS Adult respiratory distress syndrome
E. Coli Escherichia Coli
kg kilogram
LMWH Low molecular weight heparin
MAP Mean Arterial Pressure
SVR Systemic Vascular Resistance
S. aureus Staphylococcal aureus
Tx Therapy
R-hirudin Recombinant Hirudin
N Subject numberThrombosis Journal 2006, 4:7 http://www.thrombosisjournal.com/content/4/1/7
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mg/kg/hr) and supportive care. Group D was the combi-
nation therapy group receiving AT, R-TPA and supportive
care.
After anesthesia was induced with intravenous pentobar-
bital, each piglet was surgically equipped with an endotra-
cheal tube for assisted ventilation, as well as central
venous, arterial and bladder catheters. After an initial sta-
bilization period of one hour, DIC was induced by inject-
ing Escherichia Coli endotoxin (800 μg/kg over 30 min).
Two animals in Group A received 1000 μg/kg. As there
were no differences in response noted between them and
the 7 animals that received 800 μg/kg of endotoxin, they
were included in the analysis. Vital signs and urinary out-
put were continuously monitored. Blood pressure,
amount of fluid resuscitation and pressor use were meas-
ured to assess our success in maintaining mean BP greater
than 30 mm Hg, as per protocol. Serial hematologic and
coagulation studies were performed (at 30 min, 1, 2, 4, 6
and 7 hours). After 7 hours, surviving animals were euth-
anized by exsanguination under deep anesthesia.
The dosages of endotoxin, AT and R-TPA were selected on
the basis of review of the literature and pilot studies.
Based on studies by Dickenite et al. (24) and Taylor et al.
(21) initial doses of endotoxin ranging from 66 to 600 μg/
kg were tested. Since these dosages did not produce hemo-
tologic evidence of DIC, the dosage was increased to 800
micrograms/kg which gave definite and reproducible
hematologic evidence of DIC and manageable hypoten-
sion in most cases.
The dosage for R-TPA was based on studies by Munoz, et
al. (15). As doses of R-TPA of 0.2 mg/kg/hr and 0.1 mg/
kg/hr were associated with ascites and hemorrhage in var-
ious organs, the dosage was decreased to 0.025 mg/kg/hr.
Finally, the AT dosage was derived from Dickenite et
al.(23) and tested in pilot studies of AT dosages ranging
from 1 unit/kg/hr to 73 units/kg/hr with and without and
boluses ranging from 5 to 250 units/kg. The lower dosages
had no effects upon clinical condition and AT levels. The
highest doses improved AT levels, but were associated
with increased hemorrhage. Eventually the dose of 50
units/kg bolus and 25 units/kg/hr continuous drip was
chosen to maximize beneficial effect and minimize side
effects.
At necropsy, macroscopic organ involvement was subjec-
tively rated by the researchers for visible evidence of hem-
orrhage in the right or left kidney, heart and liver. Scores
of 0–4 were given denoting the number of organs with vis-
ible evidence of macroscopic hemorrhage. Tissue samples
were collected for histological examination.
Piglet kidney sections were stained with hematoxylin and
eosin and evaluated microscopically in a blinded fashion
by a single pathologist, Dr. Hernan Correa. All samples
were assigned values on a scale from 0–5 (0: no involve-
ment; 1: minimal; 2: mild; 3: moderate; 4: moderately
severe; and 5: severe) for two different categories: conges-
tion which was defined by presence and amount of fluid
accumulation; hemorrhage which was defined by evi-
Table 2: Porcine and Human Coagulation Values and Reference Ranges [7,15,5]
Porcine Juvenile Human Premature 
Neonate
Human Term Neonate Human Adult
Parameter Mean ± SD £ Mean ± SD Range (mean) £ Mean ± SD Range (mean) Mean ± SD
Hct % 28.89 ± 3.88 £ 60 ± 8 £ 61 ± 7 41 ± 3.0
Plt G/L 407.32 ± 121.24 10.6–16.2 (13.0) 10.1–15.9 (13.0) 265.0 ± 57.5
AT % 100.89 ± 11.43 0.14–0.62 (0.38) 0.39–0.87 (0.63) 100.0 ± 10.0
Fib mg/100 ml 357.44 ± 88.43 1.5–3.73 (2.43) 1.67–3.99 (2.83) 285.0 ± 47.5
Table 3: Description of study groups.
Group (n) AT R-TPA Supportive Care
A (control) 9N o N o Y e s
B 6 Yes No Yes
C 6N o Y e s Y e s
D 6 Yes Yes Yes
Legend: AT: antithrombin III (50 μg/kg bolus, and 25 μg/kg continuous intravenous infusion); R-TPA: recombinant tissue plasminogen activator 
(0.025 mg/kg/hr).Thrombosis Journal 2006, 4:7 http://www.thrombosisjournal.com/content/4/1/7
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dence and degree of bleeding. In addition, thrombosis
was rated by presence (+1) or absence (0) of clot forma-
tion.
Primary outcome parameters included survival time, mac-
roscopic and microscopic organ involvement and second-
ary outcome parameters included hematocrit; platelet
count; fibrinogen level; and AT level. Blood pressure was
a clinical variable measured to assess our success in main-
taining mean BP greater than 30 mm Hg, as per protocol.
Each treatment factor (AT, R-TPA), was tested at two lev-
els. The first level compared the factor alone against sup-
portive care alone and the second level compared the
combined factors against supportive care alone. Statistical
analysis of the data was undertaken using matched pair t-
tests to compare baseline to follow-up changes for plate-
lets, fibrinogen, AT, blood pressure and hematocrit level
within each of the four groups. A permutation procedure
was used to calculate significance levels due to non-nor-
mality and heteroskedasticity across treatment groups for
blood pressure. A permutation test was also used to com-
pare groups on number of organs displaying macroscopic
organ involvement. Survival time across groups was com-
pared using a survival model assuming exponentially dis-
tributed survival times with survival time censored at
seven hours. P-values are from one-way statistical tests
and are not adjusted for multiple testing, as these analyses
are considered exploratory rather than confirmatory. All
analyses were done using Stata 8.2.
This project was reviewed and approved by the Louisiana
State University Institutional Animal Care and Use Com-
mittee.
Results
Clinical parameters
Blood pressure
Mean blood pressures fell (P < 0.0002) after the adminis-
tration of endotoxin (Table 4). The average change from
baseline to follow-up for BP was statistically analyzed for
each group. There were no significant differences among
the groups. Table 5 demonstrates the amount of fluids
and pressors administered to each group, following
parameter protocols for fluid resuscitation and pressor
usage. The apparent incongruity noted in Group A requir-
ing the least amount of resuscitation is more than likely
secondary to the shortened survival time of these piglets.
Survival time
The survival time findings (Fig. 1) support the research
hypotheses showing a tendency for improving survival
across the groups (A < B = C < D). Mean survival times (±
SD) were 4.16 ± 3.10, 4.92 ± 3.23, 5.58 ± 2.25, and 7.00
± 0.00 hours for Groups A, B, C, and D, respectively. Mean
Table 4: Changes in blood pressure in anesthetized piglets before and after induction of DIC by intravenous administration of 
endotoxin.
Mean Blood Pressure ± SD (mm Hg) P-Value*
Group Basal Follow-up Δ B vs. C vs. D vs.
A: Supportive care 74 ± 11 32 ± 23 -42 ± 26 0.238 0.195 0.118
B: AT 70 ± 17 25 ± 13 -45 ± 26 0.970 0.382
C: R-TPA 70 ± 15 23 ± 13 -47 ± 6 0.375
D: AT + R-TPA 65 ± 13 29 ± 4 -36 ± 14
Legend: Δ is the average change of follow-up from baseline. AT: antithrombin III (50 μg/kg bolus, and 25 μg/kg continuous intravenous infusion); R-
TPA: recombinant tissue plasminogen activator (0.025 mg/kg/hr); SD: standard deviation. *P-values are based on statistical analysis of the average 
change (Δ) from baseline to follow-up for BP (paired t-test).
Table 5: Fluid and pressor usage in the 4 groups of piglets following endotoxin administration.
Group Fluid Volume (ml) Dopamine Dopamine + Dobutamine
A 107.8 ± 61.7 33% 33%
B 82.2 ± 34.6 100% 67%
C 83.7 ± 56.8 100% 50%
D 121.7 ± 66.8 100% 83%
*P-values 0.559 0.49 0.528
Legend: Fluid volume is the mean of total volume given in resuscitative measure for that particular group ± the standard deviation. The use of 
Dopamine and Dobutamine is expressed as percentage of animals in each group that received pressors. *P-values reflect testing for differences 
across the groups (Fisher's Exact Test).Thrombosis Journal 2006, 4:7 http://www.thrombosisjournal.com/content/4/1/7
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survival time was only significantly different between
Groups A and D (P = 0.042), suggesting that the com-
bined effect of AT and R-TPA was greater than either indi-
vidual effect. However, the small sample size is
problematic and limited the power to detect survival time
differences statistically. Moreover, censoring survival time
at seven hours may have limited detection of variation
across the groups. A longer survival time cut-off may have
allowed detection of other survival time differences.
Macroscopic and microscopic organ involvement
The data (Figure 2) suggest that R-TPA and combined
therapy reduce macroscopic organ involvement after
induction of DIC. Figure 3 demonstrates typical organ
involvement. The data shown in Fig. 4 support our
research hypothesis that combined therapy with AT and
R-TPA results in less microscopic organ involvement than
supportive therapy alone.
Hematocrit levels
The average change from baseline to follow-up for hema-
tocrit (Table 6) was statistically analyzed for each group.
The pattern of change was consistent with the research
hypotheses. Specifically, hematocrit was better preserved
in Group D than in Group A (P = 0.003) and tended to be
better than in Group C (P = 0.05).
Platelets
The average change from baseline to follow-up in platelet
level was analyzed for each group (Table 7). There were no
statistically significant differences among the groups
although the power was low due to the limited sample
size.
Fibrinogen level
The average change from baseline to follow-up (Table 8)
was analyzed for each group. There were no significant
differences found.
AT level
The data (Fig. 5) clearly demonstrate a positive effect of AT
administration upon post-endotoxin AT levels and sup-
port the research hypothesis.
Discussion
DIC is a life-threatening disease with serious mortality
and morbidity. Controversy exists concerning the efficacy
of various treatment modalities using coagulation factor
replacement [16].
Most previously published studies [17-20] used a mono-
therapeutic approach directed at either the anticoagula-
tion or fibrinolytic derangement and were performed in
children, adolescents or adults. There have been very few
reports in the literature concerning such therapies in the
neonate [20,22]. Yet, neonates, and especially premature
infants, are at increased risk for DIC due to developmental
differences in their levels of coagulation and anticoagula-
tion factors at birth [4]. This study explored the efficacy of
Macroscopic organ involvement after induction of DIC in  anesthetized piglets Figure 2
Macroscopic organ involvement after induction of DIC in 
anesthetized piglets. At necropsy, scores of 0 to 4 were given 
based on number of organs (right or left kidney, heart and 
liver) with visible evidence of hemorrhage. AT: antithrombin 
III (50 μg/kg bolus, and 25 μg/kg continuous intravenous infu-
sion); R-TPA: recombinant tissue plasminogen activator 
(0.025 mg/kg/hr). Data are expressed as mean ± SD (stand-
ard deviation). *P < 0.025, compared with supportive therapy 
alone.
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Survival curve by treatment group of anesthetized piglets fol- lowing DIC induction by intravenous administration of E. coli  endotoxin (800 μg/kg over 30 min) Figure 1
Survival curve by treatment group of anesthetized piglets fol-
lowing DIC induction by intravenous administration of E. coli 
endotoxin (800 μg/kg over 30 min). The numbers on the far 
right of each survival curve indicate the number of surviving 
animals after 7 hours as a fraction of the original number. 
Group A: supportive care only (n = 9); Group B: supportive 
care + AT (antithrombin III) (n = 6); Group C: supportive 
care + R-TPA (recombinant tissue plasminogen activator) (n 
= 6); Group D: supportive care + AT + R-TPA (n = 6).
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a dual anticoagulation and fibrinolytic agent replacement
therapy in the newborn piglet model of DIC.
Although hampered by a small sample size that limited
the power to demonstrate statistical significance, our
study results from the first level of analysis, i.e. factor
alone compared with supportive care, showed a trend
toward improved survival and less severe hematologic
and coagulation system derangements that are compara-
ble with past studies. Dickneite, et al. [21] demonstrated
that AT administered to adult pigs in porcine septic shock
decreased DIC and improved survival. Von Kries, et al.
[22] reported that AT administration improved the coagu-
lation derangement in 10 newborns with sepsis. In con-
trast to Fourier, et al [23] who reported improved mean
arterial pressure and systemic vascular resistance when AT
was used after E. Coli endotoxin was administered to adult
pigs, we found no beneficial effect of AT on blood pres-
sure in our piglets. This may reflect differences in cardio-
vascular response between neonatal and adult responses
in the pig, but could also just be due to the small numbers
and low power of our study.
DIC affects not only the anticoagulation system, but also
the fibrinolytic system. Yet, data on the fibrinolytic
approach are limited. R-TPA has been used in 3 infants
with DIC due to meningococcemia [20,24] with
improved perfusion and cardiac performance. Only one
study [11], performed in an adult rabbit model of DIC,
utilizing R-TPA and R-hirudin, addressed both anticoagu-
lation and fibrinolytic abnormalities and reported
improved hemostatic markers and decreased fibrin depos-
Photograph of right and left kidneys from A) a piglet from Group A that received only supportive care, exhibiting hemorrhages  in the renal parenchyma; and B) an animal from Group D that received supportive care, R-TPA and AT Figure 3
Photograph of right and left kidneys from A) a piglet from Group A that received only supportive care, exhibiting hemorrhages 
in the renal parenchyma; and B) an animal from Group D that received supportive care, R-TPA and AT. No hemorrhagic 
changes were seen.
A
BThrombosis Journal 2006, 4:7 http://www.thrombosisjournal.com/content/4/1/7
Page 8 of 10
(page number not for citation purposes)
its. To our knowledge, our study represents the first
attempt to utilize dual treatment of DIC in the susceptible
neonate or animal model representative of the neonate.
Our major goal was to determine if addressing both sides
of the problem in the neonatal pig after endotoxin-
induced DIC could improve survival and outcome.
Conclusion
Our very preliminary data suggests that combined therapy
with AT and R-TPA improved survival, degree of macro-
scopic and microscopic organ involvement and hemat-
ocrit in this piglet model of endotoxin-induced DIC
compared with supportive care alone. We were unable to
demonstrate such beneficial effects with the use of single
agent therapies, but this may be due to the small sample
size resulting in low power. AT administration increased
AT levels similarly whether used as a single agent or in
combination with R-TPA. Yet, the beneficial effect on sur-
vival and organ involvement was only significant in the
combined therapy group suggesting an additive effect of
the fibrinolytic component. No adverse effects, e.g. exac-
erbation of bleeding or clot formation, were found using
Table 6: Changes in hematocrits of anesthetized piglets before and after induction of DIC by intravenous administration of endotoxin.
Mean Hematocrit ± SD (%) P-Value*
Group Basal Follow-up Δ B vs. C vs. D vs.
A: Supportive care 26 ± 5 21 ± 8 -5 ± 4 0.155 0.353 0.003
B: AT 28 ± 9 26 ± 9 -2 ± 7 0.647 0.115
C: R-TPA 32 ± 5 28 ± 8 -4 ± 7 0.050
D: AT + R-TPA 27 ± 5 29 ± 6 2 ± 4
Legend: Δ is the average change of follow-up from baseline. AT: antithrombin III (50 μg/kg bolus, and 25 μg/kg continuous intravenous infusion); R-
TPA: recombinant tissue plasminogen activator (0.025 mg/kg/hr); SD: standard deviation. *P-values are based on statistical analysis of the average 
change from baseline to follow-up for hematocrit (paired t-test).
Microscopic organ involvement Figure 4
Microscopic organ involvement. After staining with hematoxylin and eosin, piglet kidney histology specimens were evaluated 
microscopically in a blinded fashion by a single pathologist and assigned values on a scale from 0–5 (0: no involvement; 1: mini-
mal; 2: mild; 3: moderate; 4: moderately severe; and 5: severe) for two different categories: congestion and hemorrhage. 
Thrombosis was rated by presence (+1) or absence (0). AT: antithrombin III (50 μg/kg bolus, and 25 μg/kg continuous intrave-
nous infusion); R-TPA: recombinant tissue plasminogen activator (0.025 mg/kg/hr). Data are expressed as Mean ± SD (standard 
deviation). Group A: n = 4; Group B: n = 5; Group C: n = 4; Group D: n = 5. * P < 0.05 compared with supportive care alone.
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these dosages in this model. Further studies with larger
numbers of subjects are obviously needed to confirm
these findings and to assess the true safety and efficacy of
the combined therapeutic approach. However, the find-
ings are encouraging and may point the way to a novel
therapeutic approach to improve mortality and the qual-
ity of life for neonates that survive an episode of DIC.
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Table 7: Changes in platelet count of anesthetized piglets before and after induction of DIC by intravenous administration of 
endotoxin.
Mean Platelet Count ± SD (× 103/cu. mm) P-Value*
Group Basal Follow-up Δ B vs. C vs. D vs.
A: Supportive care 532 ± 274 179 ± 192 -353 ± 268 0.105 0.392 0.332
B: AT 574 ± 133 357 ± 134 -217 ± 79 0.090 0.775
C: R-TPA 543 ± 74 207 ± 85 -336 ± 130 0.407
D: AT + R-TPA 666 ± 203 408 ± 274 -258 ± 262
Legend: Δ is the average change of follow-up from baseline. AT: antithrombin III (50 μg/kg bolus, and 25 μg/kg continuous intravenous infusion); R-
TPA: recombinant tissue plasminogen activator (0.025 mg/kg/hr); SD: standard deviation. *P-values are based on statistical analysis of the average 
change from baseline to follow-up for platelet count (paired t-test).
Table 8: Changes in fibrinogen levels of anesthetized piglets before and after induction of DIC by intravenous administration of 
endotoxin.
Mean Fibrinogen Level ± SD (mg/dl) P-Value*
Group Basal Follow-up Δ B vs. C vs. D vs.
A: Supportive care 144 ± 23 67 ± 27 -77 ± 34 0.102 0.786 0.571
B: AT 156 ± 26 104 ± 32 -52 ± 33 0.055 0.823
C: R-TPA 149 ± 31 60 ± 43 -89 ± 26 0.307
D: AT + R-TPA 157 ± 36 85 ± 33 -72 ± 52
Legend: Δ is the average change of follow-up from baseline. AT: antithrombin III (50 μg/kg bolus, and 25 μg/kg continuous intravenous infusion); R-
TPA: recombinant tissue plasminogen activator (0.025 mg/kg/hr); SD: standard deviation. *P-values are based on statistical analysis of the average 
change from baseline to follow-up for fibrinogen level (paired t-test).Thrombosis Journal 2006, 4:7 http://www.thrombosisjournal.com/content/4/1/7
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